Autorisation d’accès précoce refusée à la spécialité QALSODY (tofersen) dans l’indication « traitement des adultes atteints de sclérose latérale amyotrophique (SLA) associée à une mutation du gène superoxyde dismutase 1 (SOD1) ».
See also
HAS opinions and decisions
22/10/2024
eNrFmNty2jAQhu95Co/vfYJQoGPItDRpmUmmlIRppzeMsNdB1EhGBw59+spAUtKRm0ZEzSWSvLvS/vp2UXy+WeTOChjHlHTdyA9dB0hCU0zuuu749tJru+e9WjxHK3S0rOWHflR3nSRHnHfdctafAiLc/3Z99QHU98DcXs2J6XQOiXi0Tgqc+58Qn12jolzjxCuKU2cBYkbTrltIsRt1Yi6YiqK3puwHL1ACcXAYOZ6dT86Ox+OgNPYPViUHdoXIndYoECObiWQMiOgjAXeUbbWmi0mj3o46jY6RB8xHwKlkCQyRmA0ZXeEUUq2jDOUcjJxk6/QG2CoHUTrRGg/myYIbGUdztBnBcqAP+p2a7YuN8EIvarXrUdQIW61WGBq5YkdHpdeO2kSgEtJsRmFYD4AES3VoNN16gmZK60A8nuTAKAcvV0llKAcPLbZUMFrM8FKCYRKHlAmUW0of5v3HOrTkh8HySZmkmBc52vpzXpgeFWJITQNTtLC3kXIHt0zxq0zzH/aJzPPgmVGPD3SxFHEJrz6VRFRA5nJkehB9SgRsqjNqxkWxOWgRA385sz8p0deEoZzmODFln6KTBC7Go0E1+l6FGu8RhzGzh42vmKR0zV8eR8fptxR9sSOqvuKyNJrUO+03UbNpfNu+K61V1KwLqfIKgQIV5qfwZ0Ayeip5lHz1pu7F+/91u2u0aKKMVbRaniGtlGDvO0NrV8LeddtPaI1+vLg11dEXCWx7s/upNY3T7oMCzFBuoz4o1VYG/vw7sEfBX5vwLJnU262zdsPsECTTk2YmRMHfBsF6vfZniHscqcPyM/Z6JeOonNv7s2ClZ9j3UHvsWgp9uq+nz0ul6c18qqs4tVM+fH/oyLU+BDPW0fgB4tZQO7h4eXr/bpOthT18RBt7bnYtLRKYElsdlJxWPVicUC9UXsklU4D4nGW44gmnUpdxsH8+6tXioHw66tV+ASIVKUM=
4xqdZgfbWpdzfKv1
